NORCROSS, Ga., Jan. 31, 2013 /PRNewswire/ -- RayBiotech, Inc. announced today that it has executed a master services agreement with Banner Sun Health Research Institute (BSHRI) of Sun City, Arizona. Under the terms of the agreement, RayBiotech will provide priority services for the biochemical analysis of disease markers in biological samples. A particular focus of the pact will be on the characterization of key biomarkers for the study of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Financial terms were not disclosed.
RayBiotech's President, Chief Operating Officer and Co-Founder, Rani Huang stated, "We are excited about providing biomarker analysis services to BSHRI researchers. Banner Sun Health Research Institute is a unique world-class research organization that has outstanding tissue depository program, clinical center that conducts a large number of clinical trials, and research scientists who are dedicated to translational research in neurodegenerative and cardiovascular disorders. We believe that the collaboration will yield promising new opportunities facilitating early diagnosis of these devastating diseases."
BSHRI research scientists are involved in biomarker discovery research in both Alzheimer's and Parkinson's diseases. Senior Scientist Dr. LihFen Lue said, "As we continue to strive towards a better understanding of the molecular mechanisms at early stage of these neurodegenerative diseases, we also recognize the importance of identifying proteins present in the biofluid that could be used as potential disease biomarkers. Fortunately, we have more cutting-edge tools these days to do this crucial research. Raybiotech Quantibody® array is one of these very useful tools."
RayBiotech provides a valuable biochemical platform to assess both the identity and quantity of these markers in a comprehensive high-throughput format. The master service agreement with BSHRI is an important step demonstrating the dedication to provide outstanding products and service from RayBiotech to the scientific community.
About RayBiotech, Inc.
In 2001 RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are featured in thousands of publications, including: Nature, Nature Medicine, Cell, Lancet, PNAS and many others. Offering the largest selection of protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metropolitan Atlanta.
About Banner Sun Health Research Institute
Founded in 1986 as a private, nonprofit biomedical research center, Banner Sun Health Research Institute (BSHRI) conduct basic and translational research, clinical research, prevention and education programs specialized in the study of normal aging and certain age-related diseases, including Alzheimer's, Parkinson's and Parkinson's diseases, and cardiovascular disease. The Institute is the applicant organization for the Arizona Alzheimer's Disease Center, a leading statewide research program that has been recognized and supported by the National Institutes of Health (NIH). Research at the BSHRI is funded by grants from the NIH, the Michael Fox Foundation, the Alzheimer's Association, and private donations. The Institute maintains collaborations with many nationally- and internationally-recognized institutions and provides highest quality of autopsy tissues to research community through a very successful Whole Body and Brain Tissue Depository Program. The clinical center at the BSHRI also participates in many important clinical trials and biomarker discovery research.
For More Information:
Rob Burgess , PhD
Director, Business Development
|SOURCE RayBiotech, Inc.|
Copyright©2012 PR Newswire.
All rights reserved